Paricalcitol did not improve the efficacy of pembrolizumab, likely due to its short half‐life of only 5–7 h. Microbiome analysis revealed significant differences between long‐term (>12 weeks) and short‐term (<12 weeks) survival groups across treatment arms. Modulation of the tumor microenvironment will likely require more sustained VDR activity. This evidence concerns the gene VDR and neoplasm.